Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

…if a modeling assumption for purposes of estimating future EPS isn't a prediction, what is it? A worst-case number that bounds a range of likely outcomes?

It’s a quasi-worst-case scenario. Companies who issue EPS guidance always expect to be able to beat it.

p.s. Teva could have guided for generic-Copaxone entry earlier than 9/1/15, but that might have suggested they think their patent case is weak, so they chose not to do so.